Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAD202
- Development stage
- Phase 1
- Lead developer
- Radiopharm Theranostics, Ltd
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
RAD202 is a proprietary single-domain antibody (nanobody) radiopharmaceutical developed for the treatment of HER2-expressing solid tumors. It specifically targets the Human Epidermal growth factor Receptor 2 (HER2), which is overexpressed in breast cancer and several other solid tumors. The drug is designed as a therapeutic radiopharmaceutical by conjugating the nanobody to radioisotopes such as Lutetium-177 (for therapy) or Technetium-99m/Gallium-68 (for imaging). This enables targeted delivery of ionizing radiation to tumor cells while minimizing exposure to healthy tissue. Preclinical and early clinical data have demonstrated favorable biodistribution, high tumor uptake, significant inhibition of tumor growth in HER2-positive xenograft models, and prolonged survival with fractionated dosing regimens. A Phase 1 first-in-human trial evaluating safety and preliminary efficacy in advanced HER2-positive cancers is ongoing[1][4][5][6][7].
- Other names
- Lu-177 RAD202Lu177 RAD202Lu 177 RAD202
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on RAD202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAD202.